US10030016, Example 315;3-[[4-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-5-yl)phenyl]methylamino]-6-cyano-N-[(1S)-1-(3,4-difluorophenyl)ethyl]pyrazine-2-carboxamide
CAS
1289182-23-5
化学式
C27H21F2N9O
mdl
——
分子量
525.52
InChiKey
YKKMAUMRPSPIKM-AWEZNQCLSA-N
BEILSTEIN
——
EINECS
——
物化性质
计算性质
ADMET
安全信息
SDS
制备方法与用途
上下游信息
反应信息
文献信息
表征谱图
同类化合物
相关功能分类
相关结构分类
计算性质
辛醇/水分配系数(LogP):
3.9
重原子数:
39
可旋转键数:
7
环数:
5.0
sp3杂化的碳原子比例:
0.11
拓扑面积:
158
氢给体数:
4
氢受体数:
10
文献信息
HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS
申请人:Arndt Joseph
公开号:US20120208819A1
公开(公告)日:2012-08-16
The present invention provides compounds useful as inhibitors of PDK1. The present invention also provides compositions thereof, and methods of treating PDK1-mediated diseases.
The present invention provides compounds useful as inhibitors of PDK1. The present invention also provides compositions thereof, and methods of treating PDK1-mediated diseases.
HETEROCYCLIC PDK1 INHIBITORS FOR USE TO TREAT CANCER
申请人:Sunesis Pharmaceuticals, Inc.
公开号:EP3364971B1
公开(公告)日:2020-06-17
US9546165B2
申请人:——
公开号:US9546165B2
公开(公告)日:2017-01-17
[EN] HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS<br/>[FR] COMPOSES HETEROCYCLIQUES UTILISES COMME INHIBITEURS DE PDK1
申请人:BIOGEN IDEC INC
公开号:WO2011044157A1
公开(公告)日:2011-04-14
The present invention provides compounds useful as inhibitors of PDK1. The present invention also provides compositions thereof, and methods of treating PDK1-mediated diseases.